ArticleNucleic acids research2026
Modulation of rob expression accelerates development of antibiotic resistance in Yersinia enterocolitica.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Multidrug-resistant bacteria pose a severe threat to global health. Mutations in transcriptional regulators accelerate the emergence of multidrug resistance and may have a crucial impact on pathogen evolvability under antibiotic exposure. Here, we investigate these dynamics in the bacterial pathogen Yersinia enterocolitica. In this organism, we identified a high-frequency de novo mutation in the promoter of an AraC/XylS-family transcriptional regulator, Rob. This mutation arose independently during resistance evolution against three of six antibiotic classes. Sequence and structure alignments indicate that Rob is a previously uncharacterized, lineage-specific regulator in Y. enterocolitica, featuring a conserved promoter architecture. This promoter mutation resulted in robust rob overexpression, leading to the activation of multiple downstream efflux- and membrane-associated pathways. This regulatory mutation emerges early and shapes the acquisition of tetracycline resistance while also enhancing high-level enrofloxacin resistance in combination with canonical mutations in gyrA and parC. Despite being favored under antibiotic selection, rob overexpression is costly, resulting in counter-selection of the -57 G > A rob allele in the absence of antibiotics. Together, these findings identify Rob as a Yersinia-specific efflux regulator and demonstrate how regulatory mutations can transiently accelerate antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.